Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock

The role of drotrecogin alfa (activated) (DAA) in severe sepsis remains controversial and clinicians are unsure whether or not to treat their patients with DAA. In response to a request from the European Medicines Agency, Eli Lilly will sponsor a new placebo-controlled trial and history suggests the...

Descripción completa

Detalles Bibliográficos
Autores principales: Finfer, Simon, Ranieri, V. Marco, Thompson, B. Taylor, Barie, Philip S., Dhainaut, Jean-François, Douglas, Ivor S., Gårdlund, Bengt, Marshall, John C., Rhodes, Andrew
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2008
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995439/
https://www.ncbi.nlm.nih.gov/pubmed/18839141
http://dx.doi.org/10.1007/s00134-008-1266-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995439/
https://www.ncbi.nlm.nih.gov/pubmed/18839141
http://dx.doi.org/10.1007/s00134-008-1266-6

Ejemplares similares